Skip to main content

Sign up for our newsletter.

Quality journalism. Progressive values. Direct to your inbox.

For Immediate Release

Contact

Lori Ann Burd, (971) 717-6405, laburd@biologicaldiversity.org

Press Release

EPA Reapproves Glyphosate, Claims Pesticide Poses No Human Health Threat

Decision disregards independent science linking glyphosate to cancer.
WASHINGTON -

Relying on confidential industry research, the Environmental Protection Agency issued a final interim decision today to reapprove glyphosate, the active ingredient in Monsanto/Bayer’s Roundup and the world’s most heavily used pesticide.

The EPA’s assessment contradicts a 2015 World Health Organization analysis of published research that determined glyphosate is a probable carcinogen.

“The Trump EPA’s assertion that glyphosate poses no risks to human health disregards independent science findings in favor of confidential industry research and industry profits,” said Lori Ann Burd, the Center for Biological Diversity’s director of environmental health. “This administration’s troubling allegiance to Bayer/Monsanto and the pesticide industry doesn’t change the trove of peer-reviewed research, by leading scientists, that’s found troubling links between glyphosate and cancer.”

While today’s decision is called interim, the EPA’s practice is to issue interim, rather than final, decisions in its registration-review process for pesticides, which means this is akin to a final decision.

In addition to the World Health Organization’s conclusion, multiple U.S. federal agencies have acknowledged evidence of a link between glyphosate and cancer. This includes the EPA’s Office of Research and Development and the U.S. Department of Health and Human Services’ Agency for Toxic Substances and Disease Registry.

Earlier this week the EPA’s Office of Inspector General announced it’s starting an audit to assess whether the EPA’s pesticide regulatory office adheres to pesticide registration risk assessment regulations, policies and procedures.

“The EPA’s pesticide office is clearly willing to bend over backwards, including disregarding its own guidelines for evaluating cancer risks, to give the industry what it wants,” said Burd. “This pesticide is heavily used on food crops, landscaping and even playgrounds, and the public deserves unbiased answers to the basic question of whether it’s safe.”

Emails obtained in litigation brought against Monsanto/Bayer by cancer victims and their families have uncovered a disturbingly cozy relationship between the EPA and the company on matters involving the glyphosate risk assessment.

In one example, when the U.S. Department of Health and Human Services announced it would be reviewing glyphosate’s safety, an EPA official assured Monsanto he would work to thwart the review, saying, “If I can kill this, I should get a medal.”

The Health and Human Services review was delayed for three years and only recently released.

Monsanto/Bayer also enjoys broad support from the Trump White House. A domestic policy advisor in the Trump administration stated, “We have Monsanto’s back on pesticides regulation.”

###

At the Center for Biological Diversity, we believe that the welfare of human beings is deeply linked to nature — to the existence in our world of a vast diversity of wild animals and plants. Because diversity has intrinsic value, and because its loss impoverishes society, we work to secure a future for all species, great and small, hovering on the brink of extinction. We do so through science, law and creative media, with a focus on protecting the lands, waters and climate that species need to survive. 

Sanders Demands End to Medicare Premium Hike From Alzheimer's Drug

Biogen's original price for the controversial drug, he argues, "is the perfect example of why Medicare should be negotiating drug prices with the pharmaceutical industry."

Jessica Corbett ·


'Monumental Victory' as Biden Cancels Boundary Waters Mining Leases

Rep. Betty McCollum called the administration's decision "a rejection of the deeply flawed and politically motivated process under the Trump administration."

Brett Wilkins ·


Rights Groups Demand Hearings on the 'Fourth Amendment Is Not For Sale Act'

"The longer Congress waits," warned one advocate, "the stronger and more dangerous this industry will become."

Kenny Stancil ·


Democrats Urge Biden to Abandon Dangerous Trump Policies on Nuclear Weapons

With the Nuclear Posture Review, say congressional lawmakers, the president can ensure "future generations can finally be free from the nuclear sword of Damocles that hangs over all our heads."

Andrea Germanos ·


'There Is No Military Solution': Jayapal, Lee Demand Diplomacy on Ukraine

"We call upon our colleagues to allow the administration to find a diplomatic way out of this crisis," said the progressive Democrats.

Jake Johnson ·

Support our work.

We are independent, non-profit, advertising-free and 100% reader supported.

Subscribe to our newsletter.

Quality journalism. Progressive values.
Direct to your inbox.

Subscribe to our Newsletter.


Common Dreams, Inc. Founded 1997. Registered 501(c3) Non-Profit | Privacy Policy
Common Dreams Logo